当前位置: 首页 >> 检索结果
1181. Gastric emptying study before gastric peroral endoscopic myotomy (G-POEM): can intragastric meal distribution be a predictor of success?
作者: Francesco Vito Mandarino.;Sabrina Gloria Giulia Testoni.;Alberto Barchi.;Gino Pepe.;Dario Esposito.;Lorella Fanti.;Edi Viale.;Paolo Biamonte.;Francesco Azzolini.;Silvio Danese.
来源: Gut. 2023年72卷5期1019-1020页 1183. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment.
作者: Liwen Wang.;Yihao Liu.;Yuting Dai.;Xiaomei Tang.;Tong Yin.;Chaofu Wang.;Ting Wang.;Lei Dong.;Minmin Shi.;Jiejie Qin.;Meilin Xue.;Yizhi Cao.;Jia Liu.;Pengyi Liu.;Jinyan Huang.;Chenlei Wen.;Jun Zhang.;Zhiwei Xu.;Fan Bai.;Xiaxing Deng.;Chenghong Peng.;Hao Chen.;Lingxi Jiang.;Saijuan Chen.;Baiyong Shen.
来源: Gut. 2023年72卷5期958-971页
Innate immunity plays important roles in pancreatic ductal adenocarcinoma (PDAC), as non-T-cell-enriched tumour. Neutrophils are major players in innate immune system. Here, we aimed to explore the heterogeneity and pro-tumour mechanisms of neutrophils in PDAC.
1187. Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al.1189. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
作者: N Jewel Samadder.;Nathan Foster.;Ryan P McMurray.;Carol A Burke.;Elena Stoffel.;Priyanka Kanth.;Rohit Das.;Marcia Cruz-Correa.;E Vilar.;Gautam Mankaney.;Navtej Buttar.;Selvi Thirumurthi.;Danielle K Turgeon.;Michael Sossenheimer.;Michelle Westover.;Ellen Richmond.;Asad Umar.;Gary Della'Zanna.;Luz M Rodriguez.;Eva Szabo.;David Zahrieh.;Paul J Limburg.
来源: Gut. 2023年72卷2期256-263页
Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but was associated with a relatively high adverse event (AE) rate.
1190. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
作者: Maria Chiara De Santis.;Luca Gozzelino.;Jean Piero Margaria.;Andrea Costamagna.;Edoardo Ratto.;Federico Gulluni.;Enza Di Gregorio.;Erica Mina.;Nicla Lorito.;Marina Bacci.;Rossano Lattanzio.;Gianluca Sala.;Paola Cappello.;Francesco Novelli.;Elisa Giovannetti.;Caterina Vicentini.;Silvia Andreani.;Pietro Delfino.;Vincenzo Corbo.;Aldo Scarpa.;Paolo Ettore Porporato.;Andrea Morandi.;Emilio Hirsch.;Miriam Martini.
来源: Gut. 2023年72卷2期360-371页
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options. However, metabolic adaptation to the harsh PDAC environment can expose liabilities useful for therapy. Targeting the key metabolic regulator mechanistic target of rapamycin complex 1 (mTORC1) and its downstream pathway shows efficacy only in subsets of patients but gene modifiers maximising response remain to be identified.
1191. IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.
作者: Tanay Kaymak.;Berna Kaya.;Philipp Wuggenig.;Sandro Nuciforo.;Andreas Göldi.; .;Franz Oswald.;Julien Roux.;Mario Noti.;Hassan Melhem.;Petr Hruz.;Jan Hendrik Niess.
来源: Gut. 2023年72卷5期821-833页
Disruption of the epithelial barrier plays an essential role in developing eosinophilic oesophagitis (EoE), a disease defined by type 2 helper T cell (Th2)-mediated food-associated and aeroallergen-associated chronic inflammation. Although an increased expression of interleukin (IL)-20 subfamily members, IL-19, IL-20 and IL-24, in Th2-mediated diseases has been reported, their function in EoE remains unknown.
1192. Defining the key intrahepatic gene networks in HCV infection driven by sex.
作者: Emanuele Marchi.;Narayan Ramamurthy.;M Azim Ansari.;Caroline E Harrer.; .;Eleanor Barnes.;Paul Klenerman.
来源: Gut. 2023年72卷5期984-994页
The transcriptional response in the liver during HCV infection is critical for determining clinical outcomes. This issue remains relatively unexplored as tissue access to address this at scale is usually limited. We aimed to profile the transcriptomics of HCV-infected livers to describe the expression networks involved and assess the effect on them of major predictors of clinical outcome such as IFNL4 (interferon lambda 4) host genotype and sex.
1193. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
作者: Joshua Quan.;Christopher Ma.;Remo Panaccione.;Lindsay Hracs.;Nastaran Sharifi.;Michelle Herauf.;Ante Makovinović.;Stephanie Coward.;Joseph W Windsor.;Léa Caplan.;Richard J M Ingram.;Jamil N Kanji.;Graham Tipples.;Jessalyn K Holodinsky.;Charles N Bernstein.;Douglas J Mahoney.;Sasha Bernatsky.;Eric I Benchimol.;Gilaad G Kaplan.; .
来源: Gut. 2023年72卷4期802-804页 1194. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
作者: Miguel A Martin-Serrano.;Benjamin Kepecs.;Miguel Torres-Martin.;Emily R Bramel.;Philipp K Haber.;Elliot Merritt.;Alexander Rialdi.;Nesteene Joy Param.;Miho Maeda.;Katherine E Lindblad.;James K Carter.;Marina Barcena-Varela.;Vincenzo Mazzaferro.;Myron Schwartz.;Silvia Affo.;Robert F Schwabe.;Augusto Villanueva.;Ernesto Guccione.;Scott L Friedman.;Amaia Lujambio.;Anna Tocheva.;Josep M Llovet.;Swan N Thung.;Alexander M Tsankov.;Daniela Sia.
来源: Gut. 2023年72卷4期736-748页
The diversity of the tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) has not been comprehensively assessed. We aimed to generate a novel molecular iCCA classifier that incorporates elements of the stroma, tumour and immune microenvironment ('STIM' classification).
1195. Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea.
作者: Michael Camilleri.;Paula Carlson.;Joelle BouSaba.;Sanna McKinzie.;Priya Vijayvargiya.;Yorick Magnus.;Wassel Sannaa.;Xiao Jing Wang.;Victor Chedid.;Ting Zheng.;Daniel Maselli.;Jessica Atieh.;Ann Taylor.;Asha A Nair.;Nagaswaroop Kengunte Nagaraj.;Stephen Johnson.;Jun Chen.;Duane Burton.;Irene Busciglio.
来源: Gut. 2023年72卷1期54-65页
There are altered mucosal functions in irritable bowel syndrome with diarrhoea (IBS-D); ~30% of patients with IBS-D have abnormal bile acid (BA) metabolism (ABAM) and diarrhoea (summarised as BAD).
1196. Hepatic p63 regulates glucose metabolism by repressing SIRT1.
作者: Maria J Gonzalez-Rellan.;Eva Novoa.;Natalia da Silva Lima.;Amaia Rodriguez.;Christelle Veyrat-Durebex.;Samuel Seoane.;Begoña Porteiro.;Marcos F Fondevila.;Uxia Fernandez.;Marta Varela-Rey.;Ana Senra.;Cristina Iglesias.;Adriana Escudero.;Miguel Fidalgo.;Diana Guallar.;Roman Perez-Fernandez.;Vincent Prevot.;Markus Schwaninger.;Miguel López.;Carlos Dieguez.;Roberto Coppari.;Gema Frühbeck.;Ruben Nogueiras.
来源: Gut. 2023年72卷3期472-483页
p63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism.
1199. Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells.
作者: Gabriele Alfarano.;Matteo Audano.;Pierluigi Di Chiaro.;Chiara Balestrieri.;Marta Milan.;Sara Polletti.;Paola Spaggiari.;Alessandro Zerbi.;Giuseppe Riccardo Diaferia.;Nico Mitro.;Gioacchino Natoli.
来源: Gut. 2023年72卷1期109-128页
Pancreatic ductal adenocarcinomas (PDACs) include heterogeneous mixtures of low-grade cells forming pseudoglandular structures and compact nests of high-grade cells organised in non-glandular patterns. We previously reported that low-grade PDAC cells display high expression of interferon regulatory factor 1 (IRF1), a pivotal transcription factor of the interferon (IFN) system, suggesting grade-specific, cell-intrinsic activation of IFN responses. Here, we set out to determine the molecular bases and the functional impact of the activation of IFN-regulated responses in human PDACs.
1200. Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
作者: Li Zuo.;Wei-Ting Kuo.;Feng Cao.;Sandra D Chanez-Paredes.;Daniel Zeve.;Prabhath Mannam.;Léa Jean-François.;Anne Day.;W Vallen Graham.;Yan Y Sweat.;Nitesh Shashikanth.;David T Breault.;Jerrold R Turner.
来源: Gut. 2023年72卷5期870-881页
Intestinal barrier loss is a Crohn's disease (CD) risk factor. This may be related to increased expression and enzymatic activation of myosin light chain kinase 1 (MLCK1), which increases intestinal paracellular permeability and correlates with CD severity. Moreover, preclinical studies have shown that MLCK1 recruitment to cell junctions is required for tumour necrosis factor (TNF)-induced barrier loss as well as experimental inflammatory bowel disease progression. We sought to define mechanisms of MLCK1 recruitment and to target this process pharmacologically.
|